A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
NCT05489614
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
Olpasiran
Sponsor
Amgen